News Releases

Year

24 Apr '24

Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)

The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi ® and Simponi Aria ® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid arthritis Alvotech is the first company to publicly announce positive topline results from a

HTML íslensk útgáfa

19 Apr '24

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)

Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to Humira ® The agreement broadens patient access and further commitment to availability of vital

HTML íslensk útgáfa

16 Apr '24

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnson & Johnson, the

HTML íslensk útgáfa

03 Apr '24

Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024

REYKJAVIK, Iceland, April 03, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will host an audio call with a market update at 12:15 pm GMT / 08:15 am

22 Mar '24

Alvotech Announces Increase in Number of Own Shares

REYKJAVIK, Iceland, March 22, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has increased the Company´s share capital by an amount of one hundred and thirty

22 Mar '24

Transaction of Managers and Closely Associated Persons

Attached is a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons. Attachments: Managers Transaction Notification J McClellan 20240320.pdf

22 Mar '24

Transaction of Managers and Closely Associated Persons

20 Mar '24

Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

Total Revenues in 2023 were $93.4 million, up 10% from previous year Product Revenues in 2023 were $48.7 million, compared to $24.8 million in 2022, with Q4 2023 product revenues of $18.9 million, up by 37% from the same period last year Alvotech’s Simlandi™ biosimilar to Humira ® (adalimumab) was

05 Mar '24

Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET

Alvotech to host Capital Markets Day in Reykjavik and on-line on March 22, 2024 REYKJAVIK, Iceland, March 05, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today

HTML íslensk útgáfa

29 Feb '24

Alvotech Appoints Interim Chief Quality Officer

REYKJAVIK, Iceland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Christina Siniscalchi will join its corporate leadership team as interim Chief

HTML íslensk útgáfa

First page
Previous page
…
Page 9
Page 10
Page 11
Page 12
Current page 13
Page 14
Page 15
Page 16
Page 17
…
Next page
Last page

Displaying 121 - 130 of 275